DTx EAST 2019

Elli Kaplan is the co-founder and CEO of Neurotrack. Her career spans two decades in the public and private sectors, including at the White House, the State and Treasury Departments, and the United Nations Development Program. Elli has also held positions with AIG, Goldman Sachs and multiple startups. She has won SXSW’s best new startup and DEMO God awards, the J&J World Without Disease Challenge, and presented at TEDx, TechCrunch Disrupt, the Royal Society of Medicine, Wired and the New York Times. Elli has an M.B.A. from Harvard Business School.

Zack Lynch is a Managing Partner and co-founder of JAZZ Venture Partners, a San Francisco-based early stage venture capital firm focused on investing in human performance technology. He is an entrepreneur and futurist who brings a rich understanding of the forces driving the convergence of digital technologies and neuroscience and how new products and services are emerging to unlock human potential across health, wellness, learning, training, sports, enterprise and entertainment. He is the author of the best selling book The Neuro Revolution: How Brain Science Is Changing our World (St. Martin’s Press) which takes a 50 year view on how neuroscience will transform human society. Zack loves to snow board and spend time with his wife and kids.

Adam Kaufman is a health pioneer, having led the building of digital behavior change programs used by dozens of healthcare organizations and tens of thousands of consumers. A health economist, engineer and company executive, Adam speaks to audiences nationwide on the accelerating trend of chronic illness, its impact on lives and costs of care and proven approaches to arresting disease trajectories.
Recognized as a leader in patient engagement and population health, Canary Health works with health plans such as Kaiser Permanente, Humana, GEHA and Blue Shield of California to empower members to better health self-management.

Pavan Choksi is an Investment Associate at Arkitekt Ventures, an early stage healthcare venture fund based in New York City that specializes in investments in novel models of healthcare delivery including digital therapeutics and applications of frontier technology such as artificial intelligence, augmented reality, genomics, and brain machine interfaces to medicine.

Prior to Arkitekt, he was the first employee and Vice President of Corporate Development for Rx.Health, a venture-backed Mount Sinai Health System spin-off commercializing a novel Digital Medicine prescription and delivery platform. As an active member of the digital health ecosystem, he serves as Strategic Advisor to the Digital Therapeutics Alliance and NODE Health.

Passionate about building great products with great user experience! I’m also passionate about Digital Health and value-driven healthcare.

I’m lucky spending all my time bringing this world together as the CEO of DarioHealth Corp. (NASDAQ: DRIO) a leading global digital therapeutics company revolutionizing the way people manage their health across the chronic condition spectrum. By delivering evidence-based interventions that are driven by accumulated data, high-quality software and coaching, we developed a novel approach that empowers individuals to adjust their lifestyle in a personalized way.

Jo is fascinated by the convergence of mobile technology and behavioral science, especially surrounding the area of healthcare. At 2Morrow, Jo leads the research and program development efforts to make evidence-based behavior modifications programs more accessible by putting them directly in the hands of those who need them via their smartphones. Focused on drivers that affect chronic disease (i.e. smoking, weight, stress, chronic pain management), 2Morrow’s evidence-based platform makes it easier and more convenient to include behavioral science into existing health care treatment plans. 2Morrow distributes programs distributed via employers, wellness platforms, health plans, providers and public health. Jo is a past “40 under 40“ who started her career as a nurse and has worked in healthcare, education and technologies companies.

Dr. Parks’ research focuses on self-help methods for increasing well-being via books and digital technology. She is Chief Scientist for tech startup Happify, which brings the cutting edge in research-based well-being interventions to large businesses, health plans, and consumers. Her research spans across the whole spectrum of wellness, from non-distressed consumers to stressed employees, sufferers of chronic health conditions, and individuals with depression and/or anxiety. She works to pioneer new methodology in the study of digital therapeutics, especially when it comes to outcomes assessment. Her work has been published in peer-reviewed journals, and in addition to editing three books, she is also an Associate Editor at the Journal of Positive Psychology.

Jeffrey has over 10 years’ experience in healthcare services/operations, market access, reimbursement, and HEOR. Jeffrey has worked both on the industry and consulting side of pharmaceuticals, medical devices, and diagnostics. His previous experience includes global work in the US, EU, and select APAC markets, covering 30 different products. Most recently he served as the Value Development Lead for The Medicines Company and their surgery/perioperative products. He was responsible for a value and evidence based approach to access and commercialization. He graduated from Boston University with a Bachelor of Health Sciences, Master of Science in Physical Therapy, and a Master of Business Administration.

Timothy Aungst, PharmD is an Associate Professor of Pharmacy Practice at MCPHS University, Worcester, MA. He graduated from Wilkes University Nesbitt School of Pharmacy, Wilkes-Barre, PA, in 2011. Afterwards, he pursued a PGY-1 Pharmacy Practice Residency at St. Luke’s University Hospital, Bethlehem, PA, with an emphasis on Internal Medicine, Cardiology, and Geriatric Care. He then completed a fellowship program focused on geriatic care, Medicare/Medicaid and drug management, and academia. While completing his post-grad training, he started writing for multiple companies on mHealth and Digital Health, with a focus on mobile apps. Since then, he has conducted research on digital health technologies in the pharmacy space and published in multiple peer review journals and spoken at multiple venues on the topic. He hopes to inspire the pharmacy profession to further integrate digital health into patient care and raise awareness on the future possibilities posed in the coming decades.

Yvonne Yu-Feng Chan, MD, PhD, FACEP is the Director of the Center for Digital Health at the Icahn Institute of Mount Sinai. She is a national leader in digital medicine research and a board-certified Emergency physician. The mission of her Digital Health Center is to drive large-scale participation of patients in biomedical research and clinical care, by leveraging the latest digital technology and advanced analytic techniques to uncover novel insights and actionable results.

Debra is founding CEO of Palo Alto Health Sciences, a digital therapeutic company providing evidence-based, at-home, drug-free solutions in behavioral health. Freespira® is an FDA-cleared treatment for panic disorder, panic attacks and PTSD. Debra has broad operational and leadership experience in start- ups, corporate and nonprofit organizations. Prior to PAHS, Debra worked with a Bay Area incubator to develop a women’s health product, was founding CEO of Novasys Medical, and was VP/GM of a Division of Tyco, inc. (Mallinckrodt, Nellcor). Debra holds a B.A., MBA and R.R.T credentials. She has been a guest entrepreneur for 5 years as part of an HBS case study. Given her deep knowledge of digital therapeutics and medical devices, she is now an Advisor to DTxCC and a Consultant in this growing market.

Pierre Leurent, CEO and founder of VOLUNTIS, has more than 19 years of international experience in digital health in the United States and Europe. Voluntis’ mission is to improve the real-world value of therapies by providing patients and clinicians with therapeutic companion software. Its clinical-grade, regulatory-cleared mobile and cloud solutions embed advanced real-time decision support algorithms to enable patients to better manage their treatment in remote collaboration with their healthcare team. Prior to starting Voluntis in 2001, Pierre worked at GE Medical Systems, where he took part in the development of medical imaging software. He also occupied several positions at HealthCenter Internet Services, a San Francisco-based vendor of electronic medical record solutions.

André is an experienced startup executive, business and sales manager, leader, and strategist. He is an expert in inside and field sales management, pharmaceutical and medical products marketing and sales, commercial strategy planning, and healthcare topics. He has extensive knowledge in B2B and B2C business, software and hardware product portfolios and offerings in the US and Germany. His passion for the impact technology can have on a large scale has been the red thread throughout his career. André holds doctorates from the University of Würzburg in medicine and the University of Freiburg in dental medicine.

André joined Sandoz in June 2018 from his role as CSO at Thermondo GmbH, an integrated energy company offering state-of-the-art energy efficiency services and applying digital process excellence and quality management. This year, The Financial Times named Thermondo #2 fastest growing company in Europe as well as one of the 100 most influential clean-tech companies in the world.
Before that, André was Vice President of Local Sales at Zocdoc, Inc. Zocdoc is an online service that identifies in-network neighborhood physicians, books appointments, shares patient reviews, provides appointment and check-up reminders, and automatically fills in paperwork. Zocdoc is free for patients and available across the United States.

Chihiro leads business development and manages relationship with partner venture capitals for Rx+ Business in Astellas. Rx+ is a concept of new healthcare solution created by combining innovative new technology in different field and Astellas capabilities developed in pharma business. In her role, Chihiro actively seeks partnership and investment opportunities in the growing field of Rx+ business, with high focus in digital health and medical device. Chihiro has 15 years of industry experiences in research and Business Development in addition to Rx+ business. She received an MSc from Waseda University and an MBA from Tsukuba University.

Bakul Patel is Director for Division of Digital Health, at the Center for Devices and Radiological Health (CDRH), at the Food and Drug Administration (FDA). Mr. Patel is responsible for providing leadership, development, implementing, execution, management and setting strategic direction and regulatory policy and coordinate scientific efforts for digital health, software and emerging technologies.

This includes responsibilities in leading the development on policies for mobile health, health information technology, cyber security, medical device interoperability, and medical device software.

Mr. Patel also led the creation of the globally harmonized regulatory framework for “software as a medical device” (SaMD) at the International Medical Device Regulators Forum (IMDRF). The concepts, principles and vocabulary created in harmonized regulatory framework has been used as a foundation in the European union, Japan, Canada, Brazil, Australia and USFDA.
Mr. Patel is the FDA liaison between the Federal Communications Commission (FCC) and the Office of the National Coordinator (ONC).

Mr. Patel is currently leading the effort for the agency in developing an innovative software precertification program in collaboration with all stakeholders to reimagine a regulatory approach for Digital health that that aims for patients and providers to have timely access to safe and effective digital health products.
Prior to joining FDA, Mr. Patel held key leadership positions in the telecommunications industry, semiconductor capital equipment industry, wireless industry and information technology industry. His experience includes Lean Six Sigma, creating long and short- term strategy, influencing organizational change, modernizing government systems, and delivering high technology products and services in fast-paced, technology-intensive organizations. Mr. Patel earned an MS in Electronic Systems Engineering from the University of Regina, Canada, and an MBA in International Business from The Johns Hopkins University.

Dr. Gandhi is a Principal at Longwood Fund, where he creates and invests in science-based companies that develop novel solutions for major medical problems. Prior to Longwood, he was an attending hospitalist at the Massachusetts General Hospital, where he also trained as a resident physician in internal medicine. He previously held an investing role at Excel Venture Management, where he evaluated early-stage biopharmaceutical and healthcare IT investments, an operating role at Wellable, where he helped to build a mobile corporate wellness startup as its Chief Medical Officer, and consulting roles at McKinsey & Company and the TriZetto Corporation. He holds an M.D. from Harvard Medical School, an M.B.A. from Harvard Business School, where he was a Baker Scholar, a D.Phil. in medical oncology from the University of Oxford where he was a Rhodes Scholar, and a B.S. with honors in biochemistry from Case Western Reserve University. He is the Secretary/Treasurer of the Suffolk District Medical Society, the professional medical society of Boston, and is a past trustee of the Massachusetts Medical Society and Boston Medical Library.

Former Managing Director at Opus Point Partners which created, financed, & operated 10+ science companies including Cougar Biotechnology (CGRB), Chelsea Therapeutics (CHTP), TG Therapeutics (TGTX), Assembly Biosciences (ASMB), Tracon Pharmaceuticals (TCON), Fortress Biotech (FBIO), and Ziopharm Oncology (ZIOP)
Co-Founder & Owner at Klein Sun Gallery, America’s leading Chinese contemporary art gallery
Guest Lecturer, Biotechnology Program at Columbia University & 17+ years life science industry experience
Former Senior Consultant at Pfizer & Strategic Advisor at publicly traded & privately held life science companies
B.A., Brandeis University

David Amor is an FDA/ EU Quality/ regulatory expert focused on combination products and digital health. From NDAs and 505(b)(2)s to mobile app 510(k)s and Pre-INDs/ Q-subs, David has worked with over 45 medical device and pharmaceutical companies – large and small alike- supporting and/ or leading regulatory submissions and implementing quality management systems, including alignment of Agile-based SDLC programs to FDA and EU requirements. He co-founded RemindTrac in 2014 (www.remindtrac.com), a digital health company for chronic patients, that continues to pioneer mobile care management systems today, and sold his consulting firm Medgineering in 2016.

David has recently led QA/RA strategy groups at Teva within the Digital Health Group, particularly in development of Agile-based Quality Management Systems, was a Principal Consultant in the CP/DH (Combination Products, Digital Health) group at Qara Partners, and served as the in-house risk management subject matter expert at Abbott (St. Jude Medical). He has served as the Director or VP of Quality at other medical device start-ups including AdrenaCard, Calcula, Enspero Medical and various others, and led multiple organizations through 483 and Warning Letter remediation projects, namely associated with risk management and design history file deficiencies, including Pfizer (Hospira), MID, Boston Scientific and St. Jude Medical.

Matthew Tucker helps healthcare companies solve complex commercial problems so they can grow bigger and faster. With extensive experience leading commercial planning and execution across functional areas, Mr. Tucker has leveraged his leadership roles at Highmark Health, Baxter, Mylan, and a number of startups. Over the course of his career, he has led significant growth in health plan initiatives and of more than 20 medical device and pharmaceutical brands.

Megan Coder, PharmD, MBA, is Executive Director of the Digital Therapeutics Alliance. DTA’s mission is to broaden the understanding, adoption, and integration of clinically-validated digital therapeutic solutions into mainstream healthcare through education, advocacy, and research.

With more than a decade of experience in the healthcare industry, Megan’s expertise extends from strategic growth and partnership development within the digital health sector, to the direct delivery of patient care. Prior to joining DTA, Megan worked with Voluntis, Iodine, the Pharmaceutical Care Management Association, and the Pharmacy Technician Certification Board.

A proud Badger, Megan graduated from the University of Wisconsin—Madison School of Pharmacy and completed an Executive Residency in Association Management & Leadership with the American Pharmacists Association.

Edward Cox was appointed as the new Chairman of the Board and the Chief Executive Officer of Dthera in connection with the closing of the EveryStory Transaction. Mr. Cox also continues to serve as EveryStory’s President and Chief Executive Officer and Chairman and a member of EveryStory’s Board of Directors, positions he has held since February 6, 2015. Prior to that, he served as a Vice President and Executive Officer of Apricus Biosciences, Inc., a publicly traded company, since December 2009, in roles leading Commercial Development, Business Development, Investor Relations, and Corporate Development. Mr. Cox holds a Master of Science in Management degree from the Warrington College of Business Administration at the University of Florida.

Eddie co-founded Akili Interactive Labs, and as part of PureTech has co-founded two other health-focused start-ups, and helped launch their digital health initiative. He was previously a Kauffman Entrepreneur Fellow, a program sponsored by the Kauffman Foundation of Kansas City, MO, focused on healthcare entrepreneurship. Prior to that, he completed his graduate work at Yale University in the Departments of Pharmacology and Molecular Biophysics & Biochemistry, focusing on structure-based drug design, where he led a research project that identified two novel chemical scaffolds as proof-of-concept compounds for novel therapy. Eddie received his B.S. in Biochemistry from Providence College, and his M.Phil. and Ph.D. from Yale University.

Jim has over 25 years of experience harnessing innovative technologies to solve important biological measurement problems.

Shortly after joining PureTech Health in 2015, he co-founded Sonde Health to provide high-frequency clinical-grade health measurements of health and disease using voice analysis on devices that people already own. He was previously with MIT Lincoln Laboratory where he worked for 15 years to help grow new biotechnology and bioengineering capabilities and teams.

Dr. Harper received his BS in biochemistry from Furman University, his PhD in biochemistry from MIT, and was a postdoctoral research fellow at Harvard Medical School in the Center for Neurologic Diseases.

Mark Bini is the Vice President of Innovation and Member Experience at Express Scripts. Since 2008, Mark has been a key contributor to the advancement of Express Scripts’ solution portfolio. Over this time, he has worked with other thought leaders to design and employ an industry-leading, behavior-centric approach to innovation that places clients and members in the “front seat” of product development. Mark is also responsible for Express Scripts’ suite of digital therapeutic solutions that includes remote monitoring solutions for diabetes, asthma, and medication non-adherence. Mark’s approach to innovation and the solutions that have spawned from it have played a key role in Express Scripts being named to Forbes’ World’s Most Innovative Companies.

Owen is the co-founder and President of MedRhythms Inc., which he intends to lead with compassion and a commitment to excellence. He is determined to provide patients across the globe with the services necessary to recover their walking ability and regain their independence. Owen started MedRhythms as an experienced entrepreneur with a MBA degree from Harvard Business School.

Anil is a physician executive based in the Boston area and has over 20 years of global healthcare and biopharmaceutical experience. He studied medicine in Ireland and worked clinically in the Irish healthcare system before moving to the biopharmaceutical industry where he has held roles of increasing responsibility across different companies, different therapeutic areas and different geographies.

Anil’s interest in developing world healthcare started while he was studying medicine at the Royal College of Surgeons in Ireland, where he raised money to purchase medical supplies for a rural health clinic in Tanzania, East Africa, and delivered them personally as well as working in the clinic for 3 months. More recently he has been instrumental in establishing a charitable access program to rare disease medicines which is now operating across 10 countries.

Alex is a senior level global bio/pharmaceutical business leader with 27+ years of experience with large pharmaceutical, fully integrated biopharmaceutical and startup organizations. He has a proven record of building and leading business strategy and operations. In his career, Alex has driven enterprise value from portfolio strategy through to commercial launch. In previous roles, Alex has architected the structure and growth of several divisions at Biogen and helped to shape the emerging biosimilar market at Epirus Biopharmaceuticals. Alex has also worked in numerous commercial and operations roles at Genzyme, Astra Zeneca, Pfizer and Bristol-Myers Squibb.

Chuck Gammal is a Partner within the Life Sciences division at Simon-Kucher. Chuck’s focus is on helping clients navigate the challenges of developing sustainable digital businesses.

Specifically, Chuck helps digital health, medical technology, and pharmaceutical clients identify and deploy the optimal commercial model to monetize innovation.

Brent is the CEO and co-founder of Cognoa, an AI-based digital precision medicine behavioral health platform. Cognoais developing innovative digital diagnostics and digital therapeutics to change the standard of care for pediatric behavioral health and improve outcomes by enabling earlier diagnosis, treatment, and increased engagement. Brent has over 20 years industry experience working with diagnostics, therapeutics and digital consumer health. Prior to Cognoa, Brent was the co-founder and COO of WellnessFX, an award-winning digital health company that increased patient engagement by providing direct-to-consumer diagnostics and integrated telemedicine. Before working in digital health, Brent worked in product and commercial roles in Novartis, Nektar, Roche and Lily.

Edward Cox was appointed as the new Chairman of the Board and the Chief Executive Officer of Dthera in connection with the closing of the EveryStory Transaction. Mr. Cox also continues to serve as EveryStory’s President and Chief Executive Officer and Chairman and a member of EveryStory’s Board of Directors, positions he has held since February 6, 2015. Prior to that, he served as a Vice President and Executive Officer of Apricus Biosciences, Inc., a publicly traded company, since December 2009, in roles leading Commercial Development, Business Development, Investor Relations, and Corporate Development. Mr. Cox holds a Master of Science in Management degree from the Warrington College of Business Administration at the University of Florida.

Ken is a regulatory affairs and business development lead at CureApp North America. He is specialized in US regulatory compliance with a strong engineering background. Before joining CureApp, he worked for regulatory compliance and business consulting company where he completed more than 14 regulatory submissions ranging from De Novo and 510(k) to Q-subs (Pre-sub, submission issue, supplemental) and variance requests.

With a variety of regulatory submission experience for products from early to late stages of development, he is currently responsible for CureApp’s US regulatory compliance, acting as a vital liaison between Japanese and US regulatory agencies.

In Japan, CureApp recently completed a phase III clinical trial and regulatory submission to the Japanese PMDA for a smoking cessation app. CureApp would like to share insights from outside of the US regulatory environment at the DTx East meeting.

Alex is a senior level global bio/pharmaceutical business leader with 27+ years of experience with large pharmaceutical, fully integrated biopharmaceutical and startup organizations. He has a proven record of building and leading business strategy and operations. In his career, Alex has driven enterprise value from portfolio strategy through to commercial launch. In previous roles, Alex has architected the structure and growth of several divisions at Biogen and helped to shape the emerging biosimilar market at Epirus Biopharmaceuticals. Alex has also worked in numerous commercial and operations roles at Genzyme, Astra Zeneca, Pfizer and Bristol-Myers Squibb.

Anand is a respected global digital health leader—most known for his insights on and experience with technology, strategy and regulatory policy. Anand has been instrumental in WellDoc’s success and the development of BlueStar®. Since joining WellDoc in 2008, he has held core leadership positions that included Chief Data Science Officer, President and Chief Operations Officer. He holds an MS and a PhD in electrical and computer engineering, and an MBA from Carnegie Mellon University.

Kristine leads the National Healthcare Practice at Michael Best Strategies. Previously, she was the RVP of Market Development for Humana. Kristine works with healthcare start-ups focusing on tactical execution in the commercialization of their company with a focus on revenue and growth. She leverages her expansive connections in the C-suite of national payers, providers, governmental agencies and employer coalitions to bring innovation to the healthcare ecosystem while focusing on the ROI.

Dr. G. Anton Decker is the President, Health Innovation, for Bon Secours Mercy Health, an $8 billion net revenue multistate health system of 43 hospitals and 57,000employees, including 2,100 physicians and advance practice clinicians. Reporting to the CEO for Bon Secours Mercy Health, he develops innovative partnerships with a focus on data and digital innovation. Previously he was the Chief Clinical Officer for Mercy Health, a $4.5 billion net revenue health system based out of<br />
Ohio and Kentucky with system-wide oversight of clinical operations and valuebased care. He has served as the president of Mercy Health Physicians, a multispecialty medical group of over 1300 providers. Prior to Mercy Health he was the chief medical officer and chairman of the board for Banner Medical Group, Banner Health’s employed physician group of over 1300 providers located in Arizona, Alaska, Colorado, Nebraska, Nevada and Wyoming. He was the chairman of the board for Banner Health Network, Banner’s Accountable Care Organization with a network of over 2500 providers in Arizona.

At Akili Interactive Labs Mr. Hennemand is currently SVP of Strategy, Corporate & Business Development, Vincent is also leading the Immuno- Inflammation Therapeutic Unit. Prior his tenure at Akili, Vincent was previously VP Corporate Development and Operations at PureTech Health, the founding institution of Akili Therapeutic Labs. Vincent spent a decade in Pharma at Sanofi Genzyme during which he had the opportunity to hold several positions from R&D, General Management, Manufacturing and Corporate Venture (SGBV) where he was responsible for developing and managing new investment opportunities including Myokardia, Voyager Therapeutics, WarpDrive Bio and Portal Instruments. He holds an Msc in Engineering from Ecole Nationale Superieure Arts et Metiers in France, an Msc in Bioengineering from Georgia Tech, and an MBA from MIT where he received a Martin Trust Center scholarship as Healthcare Sector Practice Leader for the Institute.

Dave’s passion is for creating and scaling health innovations for existing and new brands. He joined RB, a leading consumer health & hygiene business, in 2011 where he developed and launched RB’s industry-leading sustainability strategy, betterbusiness. In 2013 his remit was expanded to incorporate the company’s innovation programme. He is currently accountable for health innovation across the infant & child nutrition, wellness, OTC and personal hygiene categories – with a focus on disruptive innovation, digital & partnerships. Before joining RB he was Head of Consultancy at Salterbaxter MSL. Prior to this, he was Head of Sustainability & Public Affairs for Kimberly-Clark EMEA . Dave has a MA in Biological Sciences from Oxford University and lives in London.

Wayne Bowden is the Vice President of Program Development at Biorasi. Wayne oversees the design, development and optimization of Sponsor projects and serves as project director on various programs including: neurology, nephrology, rare disease, and digital therapeutics, in addition to Biorasi’s many clinical trial rescues.

Kal Patel has over 20 years of experience in pharma, medtech and regulated digital health. Prior to joining BrightInsight, he was Chief Commercial Officer for Doctor on Demand, now the nation’s largest video-medicine provider, with backing from Andreessen Horowitz, Venrock, Google Ventures, and Qualcomm.

Kal founded and built Amgen’s Digital Health business unit where he had end-to-end responsibility for developing and commercializing a portfolio of digital products in connected devices, advanced algorithms/decision making and next-generation marketing, where he launched multiple regulated devices. Kal also serves as a Senior Advisor in Digital Health to the Boston Consulting Group and various digital health startups

Tami is a Medical Affairs professional with extensive experience launching game-changing therapeutics.
She currently serves as Head of Medical Affairs for Pear Therapeutics, the industry leader in digital therapeutics, and developers of the first FDA-authorized prescription digital therapeutics (PDTs). Tami has also led the Medical team for SSI Strategy, a boutique biopharma consulting firm that specializes in early-stage, innovative companies with industry-leading technologies. Tami led Medical Affairs at Spark Therapeutics, building the organization from the ground up to launch the first gene therapy for a genetic disorder in the U.S. She was previously Sr. Vice President of Global Medical Affairs for Shire Pharmaceuticals, and before that, held increasing levels of responsibility within medical affairs at Forest Laboratories and Allergan. She has also been an investment banking analyst with Bankers Trust Company. Tami received her MD from Columbia University College of Physicians and Surgeons, and her BA from Cornell University.

Sarah Jackson is Chief of Staff at Click Therapeutics, where she operates across business development, alliance management and strategy. In her role, Sarah actively seeks partnership and licensing opportunities, supports deal execution, and manages collaboration relationships and operations. Sarah holds a B.A. cum laude in Cognitive Neuroscience and Evolutionary Psychology from Harvard College.

Omri is the CEO & co-founder of Medisafe. In 2012 he founded Medisafe after his diabetic father accidentally double-dosed on insulin. Tapping into his considerable entrepreneurship experience, Omri successfully grew Medisafe into the leading medication management platform with over 5M users worldwide partnering with global pharma clients to develop digital health programs.

Joel serves as Chief Commercial Officer for Click Therapeutics. Click develops software as prescription medical treatments to improve the lives of patients throughout the world.
For over 25 years Joel has helped payers, employers, providers and suppliers achieve better patient outcomes at a lower cost of care using new health technology. Helping to lead the charge for healthcare innovation, Joel will share how employers, insurers, and other healthcare payers are adopting Click’s clinically-validated digital therapeutics as key components to population health strategies.
While at Johnson & Johnson as Director of Payer Relations and with Walgreens as Vice President of Market Development Joel initiated pay for performance and shared savings models of value-based purchasing with payers and health systems. Joel also led commercial efforts with Sanofi Aventis to help providers contain the exploding costs associated with chronic conditions such as diabetes and cardiovascular disease.
Joel graduated from DePaul University in Chicago and later completed a Fellowship in healthcare leadership with the Washington DC based Advisory Board Company.

Cris De Luca is currently the Global Director of Digital Innovation for Johnson & Johnson Innovation, based in Cambridge, Massachusetts. He holds primary digital and data responsibilities, translating hi-tech external opportunities throughout J&J’s Innovation Centers, JLABS incubators and JJDC corporate ventures across the Pharma, Consumer and Medical Device businesses.
De Luca formerly led emerging technology programs within research informatics at Novartis Institutes for BioMedical Research. With entrepreneurial DNA, Cris is well recognized for his role in the innovation economy since Co-Founding one of the largest startup venture pitch competitions in the U.S called Ultra Light Startups, accelerating hundreds of companies in Boston, New York City and Silicon Valley.
Cris serves on the advisory boards of SXSW Health and VOICE Summit by Amazon Alexa. He was recognized as a 40 Under 40 awardee by the Boston Business Journal and Top 40 Healthcare Transformer by MM&M Magazine.

Sharief Taraman, M.D. is the Chief Medical Officer at Cognoa, Inc., a Silicon Valley based startup that develops artificial intelligence-based digital diagnostics and personalized therapeutics that provide accurate, earlier diagnoses and more effective treatments to improve outcomes and lower behavioral healthcare costs. He is a Magna Cum Laude graduate of the University of Michigan having majored in Biochemistry. He completed his medical education at Wayne State University School of Medicine in 2006 and went on to complete residency training in Pediatrics and Pediatric Neurology at the Children’s Hospital of Michigan. Dr. Taraman is dual board certified in Neurology with special qualifications in child neurology from the American Board of Psychiatry and Neurology and in Clinical Informatics from the American Board of Preventative Medicine. He remains clinically active as the Division Chief of the CHOC Children’s Specialists Pediatric Neurology Division and a Health Sciences Associate Clinical Professor at UC Irvine School of Medicine. Dr. Taraman is active in the community as a board member of the AAP Orange County Chapter, Irvine Unified School District Medical Advisory Board, and volunteering for Girl Scouts of Orange County and the Capistrano Unified School District.

Carlos Rodarte is a systems thinker and business innovator, committed to enabling individuals to discover how their behaviors, biology and environment impact health outcomes. As SVP, Life Sciences Strategy & Business Development at Health Catalyst, Inc., he is helping shape the life sciences industry to become more patient-centered, and outcomes-focused.